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ORIGINAL RESEARCH ARTICLE
miRNA profiling of circulating EpCAM extracellular
vesicles: promising biomarkers of colorectal cancer
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Cancer cells secrete small membranous extracellular vesicles (EVs) into their microenvironment and
circulation. These contain biomolecules, including proteins and microRNAs (miRNAs). Both circulating
EVs and miRNAs have received much attention as biomarker candidates for non-invasive diagnostics. Here we
describe a sensitive analytical method for isolation and subsequent miRNA profiling of epithelial-derived EVs
from blood samples of patients with colorectal cancer (CRC). The epithelial-derived EVs were isolated by
immunoaffinity-capture using the epithelial cell adhesion molecule (EpCAM) as marker. This approach
mitigates some of the specificity issues observed in earlier studies of circulating miRNAs, in particular the
negative influence of miRNAs released by erythrocytes, platelets and non-epithelial cells. By applying this
method to 2 small-scale patient cohorts, we showed that blood plasma isolated from CRC patients prior to
surgery contained elevated levels of 13 EpCAM-EV miRNAs compared with healthy individuals. Upon
surgical tumour removal, the plasma levels of 8 of these were reduced (miR-16-5p, miR-23a-3p, miR-23b-3p,
miR-27a-3p, miR-27b-3p, miR-30b-5p, miR-30c-5p and miR-222-3p). These findings indicate that the
miRNAs are of tumour origin and may have potential as non-invasive biomarkers for detection of CRC. This
work describes a non-invasive blood-based method for sensitive detection of cancer with potential for clinical
use in relation to diagnosis and screening. We used the method to study CRC; however, it is not restricted to
this disease. It may in principle be used to study any cancer that release epithelial-derived EVs into circulation.
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C
olorectal cancer (CRC) is the third most common
cancer and the fourth most common cause of
cancer deaths worldwide (1). Detection and treat-
ment of CRC at its early stages is a key to reduce the
number of cancer deaths (2). The time frame for develop-
ment from premalignant to malignant disease is typically
1015 years in individuals with sporadic disease, making
CRC an ideal target for early detection and intervention
(3). At present, the faecal occult blood test and the faecal
immune test are the only clinically implemented non-
invasive diagnostic tests for CRC (4). Unfortunately, these
tests have low compliance rates and mediocre sensitivities
(4090%) (5). Consequently, the clinical sensitivity of these
tests ranges between 12 and 76% meaning that a significant
$These authors contributed equally to the work.

Journal of Extracellular Vesicles 2016. # 2016 Marie Stampe Ostenfeld et al. This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permitting all non-commercial use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1
Citation: Journal of Extracellular Vesicles 2016, 5: 31488 - http://dx.doi.org/10.3402/jev.v5.31488
(page number not for citation purpose)
number of neoplastic large bowel lesions are undetected by
these approaches (5). Therefore, current research in the
field is focused on developing screening concepts that are
accurate as well as acceptable by the screening population.
Such concepts include blood-based procedures for which
compliance rates 90% have been reported (6).
Circulating microRNAs (miRNAs) have received much
attention as biomarker candidates for non-invasive diag-
nostics but are not yet in clinical use. Recent reviews and
meta-analyses of circulating miRNA studies in CRC
highlight that while a few miRNAs, including miR-21-
5p, miR-29a-5p and 92a-5p, are frequently found to be
dysregulated, there are also multiple studies with conflict-
ing findings (79). This may in part be due to unrecog-
nized or underestimated influence of sample processing
and other pre-analytical variables on the measured circu-
lating miRNA levels. MiRNAs are released into circula-
tion by nearly all cell types, and it has been reported that
the majority of the cell-free miRNAs found in blood
originate from blood cells (10). Moreover, studies have
reported that procedures for sample collection and
storage dramatically affect the levels of circulating miR-
NAs (7). In particular, platelet contamination and hae-
molysis have been reported to affect miRNA results
(1113). Indeed, the aforementioned miRNAs miR-21-
5p, miR-29a-5p and 92a-5p are present in red blood cells,
and their plasma levels have been shown to be strongly
affected by haemolysis (10,13,14).
MiRNAs in circulation show a remarkable stability
(15,16). It has been suggested that they are protected
against RNase-mediated degradation because they are
bound by proteins such as argonaute-2 and HDL or
encapsulated by membranous extracellular vesicles (EVs)
(1720).
EVs have recently been recognized for their intercellular
signalling role in normal physiology (21). Their abundance
in circulation is increased upon disease, including cancer
(2225). EVs have been reported to carry surface proteins
characteristic of the cell and tissue of origin. These specific
surface proteins have potential to be used as tags to identify
and isolate EVs originating from specific tissues. The
approach has been exemplified by the use of antibodies
directed against the epithelial cell adhesion molecule
(EpCAM) to isolate epithelial-derived EVs (EpCAM
-EVs) from serum of lung and ovarian cancer patients
(22,23,25). By themselves, the EpCAM-EVs are difficult
to use as biomarkers as their low abundance makes
detection and quantification non-trivial. However, some
of the biomolecules they carry, including miRNAs, may be
sufficiently abundant to be readily detected and quantified
by sensitive methods such as quantitative reverse tran-
scription polymerase chain reaction (qRT-PCR). Micro-
RNA profiling of epithelial-derived EVs potentially
overcomes some of the specificity issues observed when
profiling miRNAs directly from plasma and serum.
Consequently, miRNAs from EpCAM-EVs have poten-
tial as cancer-specific biomarkers (22,23).
In this study, we aimed to develop a method for
miRNA profiling of EpCAM-EVs isolated from plasma
and serum. This method was applied to samples from
CRC patients and healthy controls, and the results showed
that specific miRNAs were more abundant in plasma and
serum EpCAM-EVs from CRC patients than healthy
controls. Furthermore, post-operation the EpCAM-EV
miRNA levels were significantly reduced indicating that
the EpCAM-EVs originated from the CRC tumours.
The method developed and the miRNAs identified have
potential for non-invasive diagnosis of CRC and for post-
operation patient monitoring.
Materials and methods
Cell lines and culture conditions
The human colorectal adenocarcinoma cell line SW620
was cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) with 10% foetal bovine serum (FCS) and 100 mg/
mL penicillinstreptomycin (Gibco Invitrogen, Carlsbad,
CA, USA). SW620 cells were seeded at 25106 cells in a
volume of 15 mL into the lower cell chamber of CELLine
Adhere 1000 (CLAD1000) bioreactors (INTEGRA Bios-
ciences AG, Zizers, Switzerland) and maintained at high
culture density at 378C in a 5% CO2 humidified incubator
for high-yield epithelial-derived EV harvest as previously
described (26,27). For EV harvests, the medium in the
lower cell compartment of the CLAD1000 bioreactors was
replaced with serum-free Advanced DMEM (AdvDMEM,
Gibco Invitrogen), whereas the upper compartment con-
tained DMEM supplemented with D-glucose (4.5 g/L) and
10% FCS. EV-containing medium from the lower chamber
was harvested every 4896 hours. Cell line authentication
using Short Tandem Repeat (STR) profiling (Cell ID
System, Promega, Madison, WI, USA) confirmed cell line
identity.
Patient samples
For miRNA profiling of circulating EpCAM-EVs,
2 patient cohorts were included. Cohort I consisted of
6 patients diagnosed with CRC and 5 healthy control
individuals (Table I). The healthy controls were all
asymptomatic and all underwent colonoscopy, which
showed no bowel lesions. From patients and controls,
54 mL whole blood was collected. For the generation of
EDTA-plasma and serum, 27 mL of whole blood was
processed for each. Within 2 hours of the phlebotomy, all
blood samples were centrifuged at 3,000 g for 10 minutes
at room temperature after which plasma and serum were
isolated and stored at 808C until use. Twelve mL plasma
and 12 mL serum were collected from all patients and
controls. For CRC patients, the samples were collected
prior to surgery. Cohort II consisted of 7 stage III CRC
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patients who were all treated surgically with curative intent
and who were recurrence free for at least 36 months
(Table II). For all 7 patients, 9-mL EDTA blood was
collected prior to surgery (median 1 day prior) and again
6 months after surgery. These samples were processed
as described for cohort I. A total of 2 mL plasma was
collected from each visit. The study was conducted in
accordance with the Helsinki Declaration. Informed
written consent was obtained from all participants accord-
ing to ethical regulations. The research protocol for cohort
I was approved by the Central Denmark Region Commit-
tees on Biomedical Research Ethics (J. no. 1999/4678)
and the protocol for cohort II by the Danish National
Ethics Committee (H-3-2009-110).
EV purification
Samples of conditioned culture medium and plasma or
serum were diluted 1:10 in Phosphate-buffered saline
(PBS) pH 7.4 (without Ca2 and Mg2) and subjected
to centrifugation at 400g for 10 minutes to remove
whole cells, 2,000g for 15 minutes to remove cellular
debris and 16,000g for 30 minutes (2 hours for plasma
and serum samples to compensate for their higher
viscosity and slower sedimentation) to remove large
membrane vesicles and apoptotic bodies. The supernatant
was transferred to new tubes and subjected to ultracen-
trifugation at 100,000g for 70 minutes to pellet EVs.
EVs were rinsed in a large volume of PBS followed by
centrifugation at 100,000g for 70 minutes. All steps of
differential centrifugation were carried out at 48C. Re-
suspension of the EVs in 3 mL PBS (pH 7.4, without
Ca2 and Mg2) was performed over 20 hours at 48C with
gentle vortexing. Aliquots were used for total protein
measurement (Bradford), proximity ligation assay (PLA),
immunoaffinity magnetic bead isolation, immunoblotting or
fixation in 2% (w/v) glutaraldehyde in 0.04 M phosphate
buffer for transmission electron microscopy (TEM).
Immunoblotting
Immunoblotting of cellular and exosomal protein content
was conducted using primary antibodies against CD63
(BD Pharmingen), CD81 (Santa Cruz), HSP90 (Santa
Cruz) and EpCAM (E144, Abcam) followed by incuba-
tion with appropriate HRP-conjugated secondary anti-
bodies (DAKO A/S, Glostrup, Denmark).
Transmission electron microscopy
For TEM, EV pellets were fixed using 2% (w/v) glutar-
aldehyde in 0.04 M phosphate buffer, dehydrated and
embedded in Epon using a Leica EM TP tissue processor
(Leica Microsystems GmbH, Wetzlar, Germany). Ultra-
thin sections (65 nm) were cut on a Leica Ultracut UCT
ultramicrotome (Leica Microsystems GmbH, Wetzlar,
Germany). Sections were stained with 3% uranyl acetate
in water and Reynold’s lead citrate and examined in a
Phillips EM 208 transmission electron microscope (FEI,
OR, USA). A total of 32 EVs from SW620 cells were
analysed to estimate vesicle size.
Proximity ligation assay
PLA was used to evaluate the expression of EpCAM on
isolated EVs quantitatively. PLA was performed as pre-
viously described (28,29). SW620 EVs were serially diluted
into a plasma background and subjected to differential
centrifugation. EV resuspensions were concentrated by
speed-vac prior to analysis. The used EpCAM probe-
conjugated oligo sequences were: 5?oligo: 5?*TCACGG
TAGCATAAGGTGCAGTACCCAAATAACGGTTCAC
*3? and 3? oligo: 5?*GGCCTCCTCCAATTAAAG AA
TCACGATGAGACTGGATGAA*3?. Primer sequences
used for qPCR were: Forward: 5?*CGGCCTCCTCC
AATTAAAGAA*3?, Reverse: 5?*CGTGAACCGTTA
TTTGGGTAC*3?. Quantitative RT-PCRwas performed
in a total sample volume of 25 mL and PCR cycle
conditions of 1 cycle at 958C for 10 minutes followed by
40 cycles of 15 seconds at 958C and 1 minute at 608C and
finally 10 minutes at 468C. The experiment was replicated
twice.
Table I. Patient cohort I (CRC cases and healthy controls)
ID no. Age Gender
Tumour
location TNM
UICC TNM
stage
CRC, 6 68 Male Rectum T3N0M0 II
CRC, 7 50 Male Sigmoidei T3N0M0 II
CRC, 8 65 Female Descendens T3N0M0 II
CRC, 9 75 Female Sigmoidei T1N0M0 I
CRC, 10 75 Male Rectum T2N1M1 IV
CRC, 11 65 Male Transversum T3N0M0 II
Healthy, 1 41 Female   
Healthy, 2 44 Female   
Healthy, 3 61 Female   
Healthy, 4 56 Male   
Healthy, 5 67 Male   
Table II. Patient cohort II (pre- and post-operation analysis)
ID no. Age Gender
Tumour
location TNM
UICC TNM
stage
8 51 Female Rectum T2N2M0 III
9 86 Male Rectum T1N1M0 III
10 62 Female Rectum T3N1M0 III
11 81 Male Rectum T3N1M0 III
12 77 Female Coeci T3N1M0 III
13 81 Male Rectum T3N2M0 III
14a 70 Male Sigmoidei T4N1M0 III
aThe patient was treated for recurrent bladder papillomas before,
during and after the diagnosis and treatment of the colon cancer.
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Generation of the SW620 EV spike-in series
Conditioned SW620 culture medium was harvested after
3 days of culture and cleared for cells, cellular debris,
membrane vesicles and apoptotic bodies by differential
centrifugation as described above. Three independent
harvests were collected and used to assess the concentra-
tion of EVs by nanoparticle tracking analysis (NTA). On
average, the 3 supernatants contained 91.293.42109
EVs per mL (Supplementary Table I). The plasma and
serum spike-in series were generated by spiking SW620
supernatant (from a fourth independent harvest) into
either plasma or serum. Each series consisted of 6 dilu-
tion points generated by spiking 1 mL of plasma (or
serum) with incrementing (5-fold) volumes of SW620
supernatant, starting with 0.64 ml (58106 vesicles)
and ending with 2,000 ml (182109 vesicles). Serum-
free AdvDMEM was added to reach a total volume of
3 mL of each spiked sample. The 2 spike-in series were
used to optimize and to evaluate the performance of the
immunoaffinity-capture technique.
Nanoparticle tracking analysis
Concentration and size of vesicles present in conditioned
medium were analysed by NTA using the NanoSight
LM10 system (NanoSight, Malvern Instruments, Malvern,
UK) configured with a 405 nm laser and a high-sensitivity
sCMOS camera (OrcaFlash2.8, Hamamatsu C11440).
Videos were collected and analysed using the NTA soft-
ware (version 3.1), with the minimal expected particle size,
minimum track length and blur setting, all set to auto-
matic. Ambient temperature was recorded manually and
did not exceed 258C. Each sample was diluted 1:100 in
particle-free PBS and had a final volume of 1.0 mL. For
each sample, 5 videos of 60 seconds duration were recorded
generating replicate histograms that were averaged.
Immunoaffinity magnetic bead capture of EVs
Immunoaffinity magnetic bead capture of EVs from the
clinical as well as the EV-spiked dilution series was
performed in 2 steps. In step 1, the total EV isolation
was performed by differential centrifugation (described
under EV purification). In step 2, the resuspended EV
preparations were used for immunoaffinity-capture using
beads coupled to an anti-EpCAM antibody (Dynabeads†
Epithelial Enrich Cat. no. 161.02, Life Technologies). As
negative control, anti-mouse IgG antibody-coupled mag-
netic beads were used (provided by Life Technologies). To
deplete unspecific binding prior to anti-EpCAM bead
incubation, beads conjugated with anti-Giardia IgG anti-
bodies (providedbyLifeTechnologies)wereusedfor1hour.
Except for the 2 following modifications, the beads were
used according to the instructions supplied by the manu-
facturer (Dynabeads† Epithelial Enrich Whole blood and
Buffy Coat).Weused4107 beadsper3mLEV suspension
and incubated for 1 hour at 48C before commencing the
washing steps. The bead-bound EVs were used for total
RNA isolation immediately after their isolation.
Isolation of total RNA
Total RNA was isolated according to the manufacturer’s
protocol (miRNeasy Mini Kit, Qiagen) with the exception
that 1 mg MS2 carrier RNA (Roche) was added to the
QIAzol Lysis Reagent to increase the extracted RNA yield
for each sample and to minimize variation in purification
efficiency. QIAzol Lysis Reagent was added (at 6:1 volume
ratio) to the bead suspension containing bound vesicles.
The lysate was collected while sample tubes were attached
to a magnet (DynaMagTM, Life Technologies). To enable
assessment of the RNA purification efficiency, 3 RNA
species (UniSp2, UniSp4 and UniSp5 from the RNA
spike-in kit, Exiqon) were spiked into the Lysis Reagent
according to the manufacturer’s protocol. RNA yield
and purification efficiency was assessed by qRT-PCR.
The large abundance of MS2 carrier in the extracted RNA
prohibited assessment of RNA concentration and quality
by spectrometry and fluorescence-based approaches, such
as Qubit (Thermo-Fisher) and Bioanalyzer (Agilent).
miRCURY LNATM Universal RT microRNA PCR
analysis
The miRCURY LNATM Universal RT microRNA PCR
system (Exiqon) was used for cDNA synthesis and qRT-
PCR analysis of miRNA abundance as this platform was
previously reported to have superior sensitivity for miR-
NAs with low abundance (30). The approach included
adding fixed quantities of 2 RNAs to control the quality
of the cDNA-synthesis (UniSp6 and cel-miR-39-3p from
the RNA spike-in kit, Exiqon). RNAs extracted from the
spike-in series and from the plasma and serum samples
of the clinical cohorts were profiled for miRNA. From
clinical cohort I, we had available 12 mL plasma/serum;
and from cohort II, we had available 2 mL plasma. For
each sample, all the RNA extracted (50 ml eluate) was used
as input for cDNA synthesis, using the Universal cDNA
synthesis kit II (Exiqon). The spike-in series and cohort
I samples were profiled using the human miRNome
panels I and II (Ver.3) (Exiqon), which together screens
721 distinct human miRNAs and a number of controls
(including the 3 RNA purification controls, the 2 cDNA
synthesis controls and a plate-to-plate variation control,
UniSp3). For cohort I samples, the plasma/serum input
per qPCR reaction was 17 ml. Cohort II samples were
profiled using a custom Pick & Mix microRNA PCR Panel
querying 43 selected miRNAs and 5 internal controls
(Supplementary Table II) corresponding to42 ml plasma
per qPCR reaction. Accordingly, the reported data are rela-
tive to the plasma input volume. They were not normalized
further. qPCR was performed on a LightCycler 480 Real-
Time PCR system (Roche) using the thermal-cycling
parameters recommended by Exiqon.
Marie Stampe Ostenfeld et al.
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Data analysis and statistical testing
Spike-in series
For the plasma and serum SW620 EV spike-in series,
the number of identified miRNAs upon EpCAM or IgG
immunoaffinity-capture of EVs was calculated as the
number of miRNA assays with CqB40. False positive
miRNA assays were defined as assays detected with
CqB40 in all IgG (negative control) data points of
the spike-in series for plasma and serum, respectively.
Conservative miRNA detection thresholds, to be applied
on the clinical samples, were defined for both plasma and
serum. These were based on assessment of the signal-to-
noise ratio DCq (EpCAM vs. IgG) at the individual points
in the spike-in series. From 3.2 ml of SW620 EV suspension
spike-in and upwards acceptable signal versus noise values,
DCq (EpCAM vs. IgG) of 0.5 or higher was observed
(Fig. 1). Accordingly, the detection thresholds were
defined based on the IgG background signals observed
at the spike-in volume of 3.2 ml. For plasma and serum,
the average IgG miRNA-assay Cq-values at 3.2 ml were
36.9 and 36.3, respectively (Fig. 1). Conservatively, the
detection thresholds were set 1 Cq-value below the average
IgG Cq-values. Accordingly, in the clinical samples,
miRNA assays were only called as detected if CqB35.9
for plasma and CqB35.3 for serum.
Patient cohort I
Data points exceeding the detection thresholds were
filtered out, and miRNA assays defined as technical false
positive assays from the IgG immunoaffinity spike-in
series were excluded. Subsequently, the number of detected
miRNAs in each sample was calculated, and unsupervised
hierarchical clustering (similarity metric: Spearman rank
correlation; linkage method: average linkage clustering)
was performed in Multi experiment Viewer (MeV) version
4.9.0 (31). Principal component analysis (PCA) was
conducted using Gene Cluster 3.0 and Java TreeView
v1.1.6r4 (32). The cluster and PCA analyses were con-
ducted on the miRNA assays that were detected in all
cancer samples (plasma n31, serum n7). Statistical
testing for differences in the number of detected miRNAs
was conducted by Student’s t-test.
Patient cohort II
In this cohort of pre- and post-operation plasma samples
from 7 stage III CRC patients, 43 miRNAs were profiled
using a custom Pick & Mix panel. The miRNA detection
threshold established for the plasma spike-in series (Cq
B35.9) was applied. Only miRNA assays detected with Cq
values below the threshold in all 7 pre-operation samples
were included for the analysis (n26). The average DCq
(pre/post) for each individual miRNA, and for all miRNAs
together, was calculated. Significance of the Cq difference
between the pre- and post-operation measurements was
evaluated by paired Student’s t-test. For visualization of
the measured Cq-values pre- and post-operation for the
top 10 identified miRNA biomarkers, Cq35.9 was
depicted when relevant in the post-operation samples.
Results
In order to evaluate the feasibility of isolating circulating
tumour-derived EVs from CRC patient plasma for miR-
NA biomarker identification, we first evaluated methodo-
logical efficacy and accuracy using an EV spike-in system.
The CRC cell line SW620 was cultivated in bioreactors for
harvest of epithelial-derived EVs. The EVs had a mean
size of 63 nm in diameter and showed enrichment of
the exosomal markers CD63 and CD81 relative to their
cellular expression (Fig. 1a and b). EpCAM, which
has previously been detected on epithelial-derived EVs
and used for affinity-capture of EVs (23), was also enriched
(Fig. 1b). On average, 1-mL conditioned medium har-
vested after 3 days of culture contained 91.2109 EVs
(Supplementary Table I).
We next investigated if plasma samples spiked with
increasing levels of SW620 EVs also showed increasing
amounts of EpCAM protein (as measured by PLA) since
this would indicate that an EpCAM-based immunoaffinity-
capture approach for isolation of epithelial-derived EVs
would be feasible. Indeed, a dose-dependent EpCAM
signal was found in the serial plasma samples and likewise
in a series of positive control samples spiked with increas-
ing amounts of recombinant EpCAM protein (Fig. 1c,
left panel). PLA did not detect EGFR expression on
SW620 EVs (Fig. 1c, right panel), which is consistent with
a previous report stating that EGF receptors were un-
detectable on SW620 cells (33).
We then tested the feasibility and accuracy of miRNA
profiling of EVs isolated from plasma and serum using
EpCAM immunoaffinity-capture, that is, by the use
of anti-EpCAM antibodies conjugated with magnetic
beads or anti-IgG beads as negative control. Initially,
immunoaffinity-capture was conducted directly on the
plasma samples spiked with increasing amounts of SW620
EVs. However, a non-linear relationship between the spike-
in level and the measured miRNA quantities was observed
(data not shown), indicating that constituents in the
plasma affected the specificity of the immunoaffinity-
capture. This issue was overcome by isolation of EVs by
ultracentrifugation prior to bead incubation. Following
ultracentrifugation, proper dissociation and resuspension
of EVs was critical to obtain linearity. We found that
20 hours of resuspension at 48C with gentle vortexing was
needed. From plasma and serum samples spiked with
incrementing amounts of SW620 EVs, EpCAM-EVs
were isolated. RNA was extracted, and 721 human
miRNAs were profiled using the miRCURY LNATM
qRT-PCR platform (Exiqon). MicroRNA assays yielding
false positive signals, defined as assays detected in all
IgG (negative control) points of the spike-in series, were
excluded from analysis. In total, 21 and 88 miRNAs were
miRNA profiling of circulating EpCAM extracellular vesicles
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excluded from the plasma and serum analyses, respectively
(Supplementary Table III). As expected, EpCAM but not
IgG-capture led to an increased number of miRNAs being
detected in the plasma samples spiked with increasing
volumes of SW620 EV suspension (Fig. 1d). A similar
observation was made in serum although here an increasing
number of miRNAs were also detected upon IgG capture
(Fig. 1d). EpCAM-capture recovered the increasing EV
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Fig. 1. Characterization of isolated CRC cell-derived extracellular vesicles. (a) TEM analysis of EVs isolated from the bioreactor-
cultivated SW620 CRC cell line. The mean size and standard deviation of 32 EVs is indicated. (b) SW620 cells and their secreted EVs
were analysed for the expression of exosomal markers CD63, CD81, and Hsp90, as well as epithelial-specific EpCAM by
immunoblotting using 3.6 mg protein. (c) Evaluation of the quantity of EpCAM and EGFR (negative control) on SW620 EVs by
PLA. Serial dilutions of isolated SW620 EVs spiked into plasma from a healthy individual were performed and followed by PLA
analysis. As positive controls serial dilutions of recombinant EpCAM and EGFR spiked into PLA buffer were used. Shown are mean
values and standard deviations of 2 experiments. (d) Evaluation of the EpCAM immunoaffinity approach’s ability to recover known
levels of circulating EVs. As a measure of recovery, we used the number of miRNAs detected (CqB40) in the RNA extracted from the
vesicles isolated by applying the immunoaffinity-capture to series of plasma and serum samples spiked with incrementing amounts of
SW620 EVs. IgG beads were used as a negative control. (e) The mean miRNA-assay Cq-values9S.E.M. measured after EpCAM or
IgG immunoaffinity-capture of the plasma (left panel) and serum (right panel) SW620 EV spike-in series. From 3.2 ml of EV spike-in
and upwards a linear relationship between the mean Cq value and the EV input level was observed. The detection thresholds for
EpCAM were defined as 1 Cq-value below the IgG level of the 3.2 ml SW620 EV spike-in point. The dashed horizontal lines define the
detection thresholds. Below the detection thresholds the signal (EpCAM) is significantly higher than the noise (IgG) as indicated by the
grey-shaded area of the graph. P-values represent MannWhitney U tests (H0: no difference between EpCAM and IgG Cq-values). (f)
Recovery was also evaluated as the difference in average miRNA quantity (EpCAM vs. IgG beads) at each dilution point. Only
miRNAs detected with CqB40 in the EpCAM analysis were included. MicroRNAs with a signal (CqB40) in all of the IgG spike-in
series points were excluded as technical false positive assays. Depicted below the graph, is the number of miRNAs detected at each
dilution point, excluding the false positive.
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numbers of the spike-in series as illustrated by a linear
relationship between the mean miRNA Cq-values and the
spiked EV numbers for both plasma (R20.97) and serum
(R20.86) (Fig. 1e). The signal-to-noise relationship at
varying EV levels was assessed by calculating the average
^miRNA quantity (EpCAM vs. IgG) at each point in the
EV spike-in series. A dose-dependent correlation between
vesicle input and the signal-to-noise ratio was observed in
plasma (R20.98), but not in serum (R20.58) (Fig. 1f).
The latter because in serum the noise (IgG-capture)
increased with increasing SV620 EV input (Fig. 1e).
The linearity and high signal-to-noise ratio observed for
plasma were replicated twice on independent spike-in
series (Supplementary Fig. 1). In conclusion, EpCAM-
immunoaffinity-capture of EVs from plasma (and to a
lesser extent from serum) is a feasible and reliable isolation
strategy for EV-derived miRNA quantification.
CRC patients have increased abundance of
EpCAM-EV associated miRNAs
We next addressed whether plasma and serum samples
collected from CRC patients prior to surgery contained
elevated levels of EpCAM-EV miRNAs compared with
healthy individuals. We applied the EpCAM immunoaffi-
nity approach to 12 mL of sample material (plasma and
serum) and subsequently profiled 721 human miRNAs on
the RNA extracted from the isolated EVs. Indeed, many
miRNAs were detected at markedly lower Cq value
(indicating increased abundance) in CRC patients com-
pared with healthy individuals in both plasma and serum
(Fig. 2). Next, the Cq-values of the clinical samples were
compared with the Cq-values obtained from the SW620
spike-in series. This revealed for plasma that the Cq values
of the CRC samples were within the linear range of the
spike-in series, while the values obtained from the healthy
controls were at or below the EpCAM detection level
for plasma (Fig. 2a). Similar results were obtained for
serum (Fig. 2b). The higher miRNA abundance in CRC
patients was also reflected in a significantly higher number
of miRNAs being detected in EpCAM-EVs from CRC
patients than from healthy controls (Fig. 2c and d).
Generally, the results from serum varied more than from
plasma, which may be due to the poorer performance of
the immunoaffinity-capture on serum.
To further investigate whether the EpCAM-EV miR-
NA profiles reflected whether the samples were collected
from patients or controls, unsupervised PCA and hier-
archical clustering analyses were conducted (Fig. 3).
Prior to analysis, false positive miRNA-assays (positive in
all IgG spike-in samples) and assays that were not detected
in all cancer samples were filtered out resulting in 31
and 7 miRNA-assays for plasma and serum, respectively.
Unsupervised PCA analysis based on these miRNAs
demonstrated near complete separation of healthy and
diseased individuals in both plasma (Fig. 3a) and serum
(Fig. 3b). More variation was observed between healthy
individuals than between CRC patients. Similar to the
PCA analysis, unsupervised hierarchical clustering showed
near complete separation of healthy individuals and CRC
patients (Fig. 3c and d). A total of 13 (plasma, Table III)
and 7 (serum, Table IV) miRNAs were significantly more
abundant in the CRC than the healthy control samples
(pB0.05, Student’s t-test). Three miRNAs (miR-16-5p,
miR-23a-3p and miR30b-5p) were significant for both
plasma and serum (Fig. 3e). In conclusion, the miRNA
profiles of EpCAM-EVs distinguish CRC from healthy
controls. Both the number of miRNAs detected and their
abundance was increased in the EpCAM-EVs of the
CRC patients compared with the controls.
EpCAM-EV-associated miRNA levels in circulation
are reduced upon surgical tumour removal
We next analysed whether surgical removal of the primary
CRC tumour affected the levels of circulating EpCAM-
EV miRNAs. Circulating miRNAs were examined pre-
and post-operation in a patient cohort comprising 7 stage
III CRC patients (Table II). All patients were considered
surgically cured based on 3 years of disease-free follow
up. Only plasma samples were analysed due to the superior
assay specificity observed in plasma. EpCAM-EVs were
isolated from 2 mL plasma using the same EpCAM bead
affinity-capture approach applied to patient cohort I.
The EpCAM-EVs were subsequently profiled using a
43 miRNA custom-designed miRCURY LNATM qRT-
PCR Pick & Mix panel. The 43 miRNAs in the panel were
selected because they were reliably detected in the CRC
samples of cohort I (Supplementary Table II), that is, they
were detected in either all CRC plasma or all serum
samples. Given the reduced number of miRNAs profiled
(43 vs. 721 miRNAs) on cohort II compared with cohort
I, it was possible to reduce the plasma input volume from
12 to 2 mL and still ensure that the amount of input
EpCAM-EV cDNA available per miRNA qPCR reac-
tion was 3 higher for cohort II than for cohort I.
The results showed that the overall number of miRNAs
detected in the EpCAM-EVs decreased upon surgical
removal of the primary tumour (Fig. 4a). A comparison
of the average miRNA abundance before and after surgery
for the 26 miRNAs detected in all the pre-operation
samples revealed a significant reduction (pB0.00001,
paired Student’s t-test) in miRNA abundance after surgery
(Fig. 4b). Nine of the 26 miRNAs were significantly less
abundant in the post-operation samples (pB0.05, paired
Student’s t-test, Fig. 4c and Supplementary Table IV).
In support of these miRNAs originating from the CRC
tumours, 8 of them were among the miRNAs significantly
more abundant in plasma from CRC patients compared
with healthy controls (Fig. 3e and 4c, and Supplementary
Table IV). In Fig. 4d, we show the pre- and post-
operation Cq values for all 7 patients for 10 of the
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19 significant miRNAs. The post-operation miRNA levels
were reduced for 6 of 7 patients (Fig. 4d). But for the
last patient (ID no. 14), no-change or an increase was
often seen post-operation. Clinically, this patient was
distinct from the rest of the patients. Over a period of
more than 14 years, including the period with treatment for
CRC, the patient was diagnosed with, and treated for,
numerous recurrent Ta-bladder papillomas. These lesions
may release EpCAM-EVs into the circulation potentially
explaining why no reduction in miRNA levels was seen
post-CRC-operation.
Discussion
For studies investigating the diagnostic potential of
circulating miRNAs in blood, there is an unmet need
for a method that is unaffected by miRNAs released to
the circulation during pre-analytical handling of the
samples, for example, through lysis of erythrocytes and
platelets. Here, we have addressed this need and devised a
method for miRNA profiling of EpCAM-EVs isolated
from plasma and serum. This approach is, in principle,
unaffected by miRNAs released by non-epithelial cells as
these are not associated with EpCAM.
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Fig. 2. Increased miRNA abundance associated with EpCAM extracellular vesicles in plasma and serum of CRC patients.
Representative examples of miRNA amounts detected in EpCAM-EVs in (a) plasma or in (b) serum from healthy individuals and
CRC patients compared to the amount detected when SW620 EVs were spiked into (a) plasma or (b) serum from a healthy individual.
The miRNA abundance in CRC plasma samples represented an acceptable signal as compared to the signal-to-noise window of
EpCAM (signal) s. IgG (noise) bead spike-in series. (c) The number of miRNAs detected in EpCAM-EVs isolated from plasma and
serum of healthy individuals and CRC patients (Patient cohort I). Following criteria were used: i) All false positive miRNAs assays were
excluded, ii) Only miRNAs detected in clinical samples at CqB35.9 (plasma) and CqB35.3 (serum) were included. Plasma from
healthy individual 3 was excluded based on an extreme outlier profile in the initial quality check. (d) Box plot of the number of miRNAs
detected from isolated EpCAM-EVs (Student’s t-test, *pB0.05, **pB0.01).
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The performance of the approach was tested using
EpCAM-EV spike-in series with up to 3 orders of magni-
tude difference in EpCAM-EV content. A linear relation-
ship between the measured miRNA quantities and the EV
input levelswas obtained in both plasma and serum. Further-
more, the miRNA quantities measured from the EpCAM
-EVs were significantly higher than the background miRNA
quantities obtained by immunoaffinity-capture using an
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unspecific IgG-antibody. Thiswas particularly evident for the
analysis of plasma where the miRNA background signals
remained negligible across the whole range of EpCAM-EV
inputs. Also for serum, the miRNA signals from the EpCAM
immune-capture were higher than the IgG background
although the background level increased with increasing
input amounts of EpCAM-EVs, indicating that our
approach is less specific in serum than plasma. The reason
for this discrepancy between plasma and serum remains
unknown. Implementation of a pre-clearing step using anti-
Giardia IgG beads prior to EpCAM beads did not improve
the signal-to-noise ratio in the spike-in series at low EV
amounts (data not shown).
Importantly, when we applied the approach to plasma
and serum samples from CRC patients and compared
the obtained miRNA signals with those obtained from the
spike-in series, we found that they were generally above the
detection limit and within the linear range of the approach.
This indicates that the plasma/serum input we use per
qPCR-reaction (]17 ml) is sufficient for reliable miRNA
quantification. Given that EpCAM-EVs are not ex-
pected to be abundant in the blood of healthy individuals,
we did not expect prominent miRNA signal in the healthy
control samples, and indeed, the majority of the queried
miRNAs were either undetectable or detected at the
limit of sensitivity in the control samples. In agreement
with this, PCA as well as unsupervised hierarchical
clustering analysis based on the miRNAs detected in the
CRC samples also separated CRC and control samples.
Moreover, these analyses indicated that miRNA profiles
of the healthy individuals varied more than that of the
CRC patients. This may reflect that the level of EpCAM-
EVs is lower in healthy individuals and that the organ
of origin for the EVs (and consequently, their miRNA
content) varies more between healthy individuals than
CRC patients.
Table III. MicroRNAs with significantly different abundance in EpCAM-EVs from plasma of CRC patients and healthy controls
CRC Healthy ctrl
Average log2 fold change
miRNA Detected in # samplesa Mean Cq Detected in # samplesa Mean Cqb (CRC vs. ctrls)b t-testb
hsa-miR-23b-3p 6 34.6 0 40.0 5.4 0.00000
hsa-miR-222-3p 6 34.8 0 40.0 5.2 0.00000
hsa-miR-142-3p 6 30.5 4 33.9 3.5 0.00027
hsa-miR-451a 6 30.5 4 33.5 3.0 0.00135
hsa-miR-23a-3p 6 32.4 4 34.6 2.2 0.00750
hsa-miR-223-3p 6 29.5 4 31.8 2.3 0.01084
hsa-miR-30b-5p 6 34.0 1 38.9 4.9 0.01696
hsa-miR-16-5p 6 31.9 4 34.5 2.6 0.01849
hsa-miR-221-3p 6 34.1 1 38.8 4.7 0.02344
hsa-miR-27a-3p 6 32.6 4 34.9 2.2 0.02370
hsa-miR-30c-5p 6 34.3 1 38.9 4.6 0.02562
hsa-miR-107 6 33.5 1 38.6 5.1 0.03453
hsa-miR-27b-3p 6 34.2 1 38.7 4.5 0.04031
aA total of 6 CRC and 4 healthy control plasma samples were analysed. bFor undetected miRNAs the missing Cq value was replaced by
an arbitrarily set background value of 40. Accordingly the fold changes and P-values should be interpreted with caution.
Table IV. MicroRNAs with significantly different abundance in EpCAM-EVs from serum of CRC patients and healthy controls
CRC Healthy ctrl
Average log2 fold change
miRNA Detected in # samplesa Mean Cq Detected in # samplesa Mean Cqb (CRC vs. ctrls)b t-testb
hsa-miR-101-3p 6 32.7 0 40.0 7.3 0.00002
hsa-miR-15b-5p 6 32.3 0 40.0 7.7 0.00003
hsa-miR-423-3p 6 33.7 0 40.0 6.3 0.00011
hsa-miR-30b-5p 6 32.9 0 40.0 7.1 0.00012
hsa-miR-199a-5p 6 33.6 0 40.0 6.4 0.00020
hsa-miR-23a-3p 6 31.8 1 38.9 7.1 0.00135
hsa-miR-16-5p 6 31.2 3 36.6 5.3 0.01606
aA total of 6 CRC and 5 healthy control serum samples were analysed. bFor undetected miRNAs the missing Cq value was replaced by an
arbitrarily set background value of 40. Accordingly the fold changes and P-values should be interpreted with caution.
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We generally observed more variation in the results
obtained from serum than from plasma, which probably
relates to the poorer performance of the immunoaffinity-
capture approach on serum. We also detected fewer
differentially expressed miRNAs (cases vs. controls) in
serum than plasma (7 vs. 13) consistent with serum being
a poorer starting material for the developed approach.
Nevertheless, 3 of the 7 differentially expressed serum
miRNAs (43%) were also differentially expressed in
plasma, indicating that some of the signal seen in serum
may be informative, despite of the higher noise. Due to
the lower variation and superior specificity, we focused on
the plasma results.
Our finding that miRNA profiling of epithelial-derived
EVs can distinguish between plasma from CRC patients
and healthy controls was corroborated when we compared
plasma samples collected pre- and post-CRC-operation.
Consistent with the reduced tumour burden, the miRNA
signals measured in the post-operation samples were
significantly lower than in the pre-operation samples for
6 out of 7 patients. The 7th patient, like the other patients,
was clinically relapse free for 36 months and as such likely
cured of CRC. However, in contrast to the others, this
patient had recurrent bladder neoplasia both concomitant
and after the CRC surgery. The bladder lesions could
potentially be the source of the detected post-CRC-
operation EpCAM-EV miRNAs. While an increase in
EpCAM-EV miRNA abundancy distinguishes healthy
individuals from cancer patients, it will likely not allow
distinction between different types of epithelial-derived
cancers. In principle, it should be possible to develop
the method further and perform the immuno-capture with
cancer subtype- or organ-specific markers. However, this
necessitates the availability and identification of specific
surface marker proteins. Additional studies are needed to
address this.
We found 8 miRNAs with higher EpCAM-EV
abundance in plasma from CRC patients than healthy
controls and lower abundance in post- versus pre-
operation plasma (Fig. 4c). We speculate that these are
of tumour origin and may hold potential as non-invasive
biomarkers. One should note though that these encoura-
ging findings were based on small sample numbers and
need to be confirmed in larger cohorts. All 8 miRNAs
have previously been reported to be functionally related to
the development of CRC, metastasis and/or prognosis.
Comparison of normal mucosa and tumour tissue indi-
cates that 5 of the 8 are downregulated (miR-16-5p (34),
miR-23b-3p (34), miR-27b-3p (34), miR-30b-5p (34) and
miR-30c-5p (34)) and 3 upregulated in tumours (miR-
23a-3p (35,36), miR-27a-3p (3437) and miR-222-3p
(37,38)). Both down- and upregulation may be consistent
with our observation of increased levels in blood. We have
recently published a study indicating that exosome-
mediated secretion of miRNAs (including miR-23b-3p)
from cancer cells may represent a cellular disposal route of
tumour- or metastasis-suppressor miRNAs (39). In this
study, the cellular export of miR-23b was found to be of
advantage to the primary tumour since its high cellular
presence would otherwise restrain proliferation, invasion,
anoikis and capacity of cancer cell lung colonization in
vivo (39). On the contrary, secretion of tumour-derived
EVs may also be a way to prime distant sites into pre-
metastatic niches to allow for micrometastases to establish
(40). There is, thus, a complex interplay between deregu-
lated miRNAs in the primary tumour tissue, the selection
of miRNAs being secreted through EVs, and their impact
on distant organs to prime for metastases. The expression
of 2 of the 8 miRNAs (miR-23b-3p and miR-30-5p) has,
furthermore, been shown to correlate with survival of
CRC patients (41). Consistent with our findings, increased
plasma and/or serum levels have previously been reported
in CRC for 3 of the 8 miRNAs (miR-23a-3p (15,42,43),
miR-30b-5p (44) and miR-222-3p (45)). It is worth
noting that other miRNAs have also been reported to be
deregulated in crude plasma/serum samples from CRC
patients but were undetected or inconsistently detected in
our EpCAM-EVs. Among the most frequently reported
are miR-18a-5p, miR-21-5p, miR-29a-5p, miR-92a-5p,
miR-143-5p and miR-378-5p (reviewed in (7)). Of these,
miR-21-5p, miR-29a-5p and miR-92a-5p are known to be
expressed by red blood cells, and it has been suggested that
this cell type may be the major source for these miRNA
in plasma/serum (7). In situ hybridization studies of
colorectal adenocarcinomas have furthermore revealed
that miR-21-5p and miR-143-5p are expressed primarily
by mesenchymal cells and not cancer cells (46,47). To the
best of our knowledge, the cellular origin of miR-18a-5p
and miR-378-5p are currently unknown. Of the 6 miR-
NAs, only miR-21-5p was detected in EpCAM-EVs, and
this inconsistently, as it was only observed in cohort II.
Accordingly, our findings are consistent with the notion
that the primary cellular origin of these miRNAs is not
colonic epithelia and moreover indicate that EpCAM
-EV profiling, with its improved specificity, may be super-
ior to crude plasma/serum profiling.
Normalization remains a major challenge in the
analysis of circulating miRNAs (7,48). In this study, we
report the EpCAM-EV miRNA Cq-values relative to
the plasma input volume used per qPCR-reaction (17 ml
plasma for cohort I and 43 ml plasma for cohort II). This
was done because we wanted the miRNA differences
(between cases and controls for cohort I and between pre-
and post-operation plasma for cohort II) to reflect
changes in both EV abundancy and EV miRNA content.
Accordingly, we cannot determine if the observed quan-
tity changes are due to changes in EV abundance or in EV
miRNA abundance, or both. To the best of our knowl-
edge, no reference marker besides plasma input has yet
been reported for normalizing circulating EV miRNA
miRNA profiling of circulating EpCAM extracellular vesicles
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Fig. 4. Circulating EpCAM-EV-derived miRNAs are reduced following CRC surgery. (a) The number of miRNAs detected before
and after surgery. EpCAM-EVs were isolated from matched pre- and post-operation plasma from 7 stage III patients. From these, the
abundance of 43 miRNAs associated with EpCAM-EVs were profiled using a custom-designed Pick & Mix qRT-PCR panel. A
miRNA was considered detected if it was below the previously defined threshold of CqB35.9. Individual patient ID numbers are
displayed. (b) 26 miRNAs were detected in all 7 pre-operation samples and shown are average abundance of these in pre- and post-
operation samples. The increased Cq values observed in the post-operation samples relative to the pre-operation samples indicate
reduced abundance. The data are depicted as the average abundance in all CRC samples. (c) A volcano plot of the 26 individual
miRNAs showing the relationship between statistical significance (paired Student’s t-test) and the fold-change between pre- and post-
operation samples (^Cq (pre  post)). The dashed line indicates p0.05. MicroRNAs with distinct abundance in EpCAM-EVs in
plasma samples from CRC patients and healthy controls are marked in red. (d) Shown are paired pre- and post-OP Cq-values for 10
selected EpCAM-EV miRNAs with significant difference in pre- and post-operation abundance.
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data (7,48). It has been reported that the input plasma
volume may affect miRNA purification efficiency (49).
Since our input was 12 mL for cohort I and 2 mL for
cohort II, variable purification efficiencies may have
affected the absolute Cq values obtained. However, we
expect that it has only minor influence on the DCq values
(CRC vs. controls and pre- vs. post-operation) we use to
compare the 2 cohorts, at least for the miRNAs that are
detectable in both cohorts. Nevertheless, it may be part of
the explanation why the consistency between the cohorts
is not complete.
A few studies have previously reported on miRNA
profiling of EpCAM-EVs isolated from plasma/serum
of lung- and ovarian-cancer patients (22,23), but none so
far from CRC patients. While each of these studies used
unique approaches for the isolation of the EpCAM
-EVs, they identified a number of miRNAs with promis-
ing diagnostic potential, similar to this study. This indi-
cates that the suggested approach is feasible and generally
applicable to epithelial-derived tumour types.
Importantly, the approach we report is not inherently
restricted to analysis of miRNAs. All epithelial-derived
biomolecules present in or on EVs could in principle be
investigated for their biomarker potential, for example,
mRNAs, long non-coding RNAs, proteins and lipids.
Further studies are needed to investigate the biomarker
potential of these biomolecules.
In summary, we report on the development of a non-
invasive approach for miRNA profiling of epithelial-
derived EVs isolated from blood. This approach mitigates
many of the specificity issues observed in earlier studies
of circulating miRNAs and their biomarker potential
in relation to epithelial cancers. Using the approach, we
identified 8 miRNAs that were more abundant in the
blood circulation of CRC patients than healthy controls
and whose abundance dropped significantly upon surgical
removal of the primary tumour. While the reported results
are promising, the approach and miRNA markers need to
be validated in larger patient cohorts before their clinical
value can be confidently affirmed.
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